ArticleJMA journal2024
Clinical and Biochemical Parameters in Relation to Serum Fetuin-A Levels in Overweight and Obese with and without Metabolic Syndrome in the North-eastern States of Indian Population.
Article in JMA journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fetuin-A: a potential molecular link between obesity, diabetes (type 2 and type 1) and metabolic steatotic liver disease (MASLD).Journal of endocrinological investigation · 2026Article
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Effects of Omega-3 Fatty Acid Supplementation on Serum Fetuin-A Levels in Patients With Coronary Artery Disease.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: This comparative study included 200 subjects (50 control, 50 overweight, 50 obese without metabolic syndrome and 50 obese with metabolic syndrome) aged 20-70 years. Lipid profile and fasting blood glucose, were measured using a fully automated analyzer. ELISA was employed to measure serum fetuin-A levels. Statistical analyses were conducted using SPSS versions 23.0. Furthermore, Results: Overweight and obese adults with and without metabolic syndrome had higher fetuin-A levels were than the controls. The results of this study indicated a positive correlation between fetuin-A and lipid profile, anthropometric parameters, 12 h fasting blood glucose and blood pressure. Contrarily, HDL-C exhibited a negative correlation with fetuin-A. Conclusions: Fetuin-A is the first hepatokine associated with metabolic diseases. It controls the entire energy homeostasis of the body probably by regulating glucose and lipid metabolism. The current data belief is that fetuin-A may be a promising biomarker for predicting metabolic syndrome and its associated disorders particularly in overweight and obese adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.